OBJECTIVES: Although anemia is known to influence clinical outcomes in heart failure (HF) patients, little is known about its impact on economic outcomes. A retrospective analysis was performed to determine the impact of hemoglobin (Hb) level on hospital length of stay (LOS), total charges, and hospital mortality in HF patients. METHODS: Claims data were drawn from 21 teaching and nonteaching hospitals for patients hospitalized between October 1, 2000 and September 30, 2001. The impact of Hb on LOS, charges, and hospital mortality was determined using multivariate analyses. Two-stage least squares regression methods were used to assess the potential endogeneity of the economic outcomes (LOS and total charges) and Hb level. RESULTS: Of the 8569 patients in the analysis, 40.2% had Hb < 12 g/dl and 73.8% were > or = 70 years of age. Hemoglobin had significant independent effects on all three outcomes. A 1 g/dl increase in Hb was associated with a 5.1% reduction in LOS (P < 0.001), a 4.3% decrease in charges (P < 0.001), and an 8.7% reduction in mortality risk (P < 0.001). The impact of Hb on all outcomes was greatest in younger HF patients. CONCLUSIONS: This analysis demonstrates that higher Hb is associated with reductions in LOS, charges, and mortality in hospitalized HF patients. Further clinical studies are necessary to validate the cost effectiveness of pharmacologic intervention in anemic HF patients and its impact on patient care.
OBJECTIVES: Although anemia is known to influence clinical outcomes in heart failure (HF) patients, little is known about its impact on economic outcomes. A retrospective analysis was performed to determine the impact of hemoglobin (Hb) level on hospital length of stay (LOS), total charges, and hospital mortality in HF patients. METHODS: Claims data were drawn from 21 teaching and nonteaching hospitals for patients hospitalized between October 1, 2000 and September 30, 2001. The impact of Hb on LOS, charges, and hospital mortality was determined using multivariate analyses. Two-stage least squares regression methods were used to assess the potential endogeneity of the economic outcomes (LOS and total charges) and Hb level. RESULTS: Of the 8569 patients in the analysis, 40.2% had Hb < 12 g/dl and 73.8% were > or = 70 years of age. Hemoglobin had significant independent effects on all three outcomes. A 1 g/dl increase in Hb was associated with a 5.1% reduction in LOS (P < 0.001), a 4.3% decrease in charges (P < 0.001), and an 8.7% reduction in mortality risk (P < 0.001). The impact of Hb on all outcomes was greatest in younger HF patients. CONCLUSIONS: This analysis demonstrates that higher Hb is associated with reductions in LOS, charges, and mortality in hospitalized HF patients. Further clinical studies are necessary to validate the cost effectiveness of pharmacologic intervention in anemic HFpatients and its impact on patient care.
Authors: Melissa C Caughey; Christy L Avery; Hanyu Ni; Scott D Solomon; Kunihiro Matsushita; Lisa M Wruck; Wayne D Rosamond; Laura R Loehr Journal: Am J Cardiol Date: 2014-09-28 Impact factor: 2.778
Authors: Donald S Silverberg; Dov Wexler; Adrian Iaina; Shoshana Steinbruch; Y Wollman; Doron Schwartz Journal: Int Urol Nephrol Date: 2006 Impact factor: 2.370
Authors: Larry A Allen; Kevin J Anstrom; John R Horton; Linda K Shaw; Eric L Eisenstein; G Michael Felker Journal: J Card Fail Date: 2009-12 Impact factor: 5.712
Authors: Shelby D Reed; Yanhong Li; Stephen J Ellis; John J Isitt; Sunfa Cheng; Kevin A Schulman; David J Whellan Journal: J Card Fail Date: 2012-10 Impact factor: 5.712
Authors: Marita G Titler; Gwenneth A Jensen; Joanne McCloskey Dochterman; Xian-Jin Xie; Mary Kanak; David Reed; Leah L Shever Journal: Health Serv Res Date: 2008-04 Impact factor: 3.402
Authors: Jean-Christophe Luthi; W Dana Flanders; Michel Burnier; Bernard Burnand; William M McClellan Journal: BMC Nephrol Date: 2006-03-06 Impact factor: 2.388
Authors: Stefan D Anker; Josep Comin Colet; Gerasimos Filippatos; Ronnie Willenheimer; Kenneth Dickstein; Helmut Drexler; Thomas F Lüscher; Claudio Mori; Barbara von Eisenhart Rothe; Stuart Pocock; Philip A Poole-Wilson; Piotr Ponikowski Journal: Eur J Heart Fail Date: 2009-11 Impact factor: 15.534